CK-MB Mass An alternative to Tropinin I that aids in diagnosing acute myocardial infarction

The Acute Care™ CK-MB assay is an in vitro diagnostic test for the measurement of the MB iso-enzyme of creatine kinase in heparinized whole blood/plasma. CK-MB measurements can be used as an aid in diagnosing acute myocardial infarction.

  • One sample, one run, one instrument; increases efficiency in triaging chest pain patients
  • Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
  • Heparinized whole blood samples
Nous contacter

Fonctionnalités et avantages

  • One sample, one run, one instrument; increases efficiency in triaging chest pain patients
  • Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
  • Single and ready to use TestPak™ Cartridges
              o No reconstitution
              o No warming to room temperature
              o Reduction in reagent waste
              o Reduction in contamination
  • Heparinized whole blood samples
  • Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility
     

 

Approche clinique

CK-MB is found primarily in cardiac tissue.1 CK-MB can be detected at elevated concentrations following myocardial damage. Abnormal plasma CK-MB concentrations are often associated with ischemia or necrotic heart injury. The increase in CK-MB concentration is often evident within 3 to 6 hours following onset of chest pain, reaching peak concentrations within 12 to 24 hours. CK-MB concentrations will generally return to normal within 24 to 72 hours.2 The determination of CK-MB is most beneficial when samples have been drawn at appropriate time intervals post onset of chest pain.

Spécifications techniques

βhCG

Assay Range

0.3 – 150ng/mL (µg/L)

Sensitivity

0.3 ng/mL

Reproducibility (CV)

4.0% at 3.7 ng/mL

Calibration Stability

60 days

DilPak™ Automatic Dilution

Yes

Sodium Heparin Tubes

Yes

Lithium Heparin Tubes

Yes

1

2